(1S,3R)-1-(2,3-dihydro-benzofuran-5-yl)-2-(3-methylamino-propionyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid methyl ester | 691871-77-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: (1S,3R)-1-(2,3-dihydro-benzofuran-5-yl)-2-(3-methylamino-propionyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid methyl ester
• CAS: 691871-77-9
• 化学式: C₂₅H₂₇N₃O₄
• 分子量: 433.507
• InChiKey: SWDMWNHDKNDYQN-YKSBVNFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.73
• 重原子数：
  32.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  83.66
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (1S,3R)-1-(2,3-dihydro-benzofuran-5-yl)-2-(3-methylamino-propionyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid methyl ester 以 甲醇 为溶剂， 反应 48.0h， 以96%的产率得到(5aR,11S)-11-(2,3-Dihydro-benzofuran-5-yl)-7-methyl-5,5a,8,9,11,12-hexahydro-7H-7,10a,12-triaza-cyclohepta[b]fluorene-6,10-dione
  参考文献：
  名称：

  Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors

  摘要：

  The synthesis of the fused tetracyclic pyrroloquinolones 9a-i in four steps is described. The PDE5 inhibitory activities of these compounds, their selectivities against PDE1, PDE2, PDE3, PDE4 and PDE6, the preclinical pharmacokinetic assessments and the in vivo efficacy in increasing intracavernosal pressure are presented and discussed. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.044
• 作为产物：
  描述：

  2,3-二氢苯并呋喃-5-甲醛 在 碳酸氢钠 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 66.0h， 生成 (1S,3R)-1-(2,3-dihydro-benzofuran-5-yl)-2-(3-methylamino-propionyl)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors

  摘要：

  The synthesis of the fused tetracyclic pyrroloquinolones 9a-i in four steps is described. The PDE5 inhibitory activities of these compounds, their selectivities against PDE1, PDE2, PDE3, PDE4 and PDE6, the preclinical pharmacokinetic assessments and the in vivo efficacy in increasing intracavernosal pressure are presented and discussed. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.044